Johnson & Johnson is a general drug manufacturer company located in New Jersey, United States, which is part of the Healthcare sector, and is traded under the ticker JNJ on the NYSE exchange.
Johnson & Johnson stock last closed at $152.65, up 1.01% from the previous day, and has decreased 12.89% in one year. It has underperformed other stocks in the Drug Manufacturers - General industry by 0.16 percentage points. Johnson & Johnson stock is currently +1.69% from its 52-week low of $150.11, and -18.23% from its 52-week high of $186.69.
As of Mar 24, 2023, there are 2.6B shares of JNJ outstanding. The market capitalization of JNJ is $397.54B. In the last 24 hours, 5.7M JNJ shares were traded.
You need a brokerage account in order to access the NYSE market and buy JNJ stock.
Based on our analysis, eToro is the best stock brokerage. Here's why:
Get $10 towards your purchase of stock by creating an account with eToro now.Open eToro Account
Now that you've selected the best brokerage, you'll need to fill out some personal details so you can invest in JNJ stock today.
Now that you've filled out your info on one of the best stock trading apps, you can securely and quickly fund your account:
Watch the video below if you need help transferring money into your brokerage account.
After you have identified the best place to buy Johnson & Johnson stock, it's crucial to evaluate their stock before you buy, so you truly comprehend the risk as well as the upside.
WallStreetZen was created to help average investors perform better fundamental analysis.
You can see all of the due diligence checks on JNJ's stock page.
Analysts use many financial metrics, analyses, models, and charts to gauge JNJ's fair value.
Using relative valuations measures:
You can do more valuation analysis on JNJ's stock here.
Out of 12 sell side analysts who track JNJ, the consensus analyst rating on JNJ is a Buy
It's important to note that analyst ratings are not stock recommendations, nor are they investment advice.
Vamil Divan, a top 5% analyst from Guggenheim initiates coverage on JNJ with a hold rating and announces their JNJ price target of $161.00, on Mar 1, 2023.
Divan initiated his coverage on Johnson & Johnson with a Hold rating and a $161 price target.
Although he agrees with the company's decision to separate its Consumer Health Business,* and believes that the MedTech segment is showing "reasonable" signs of recovery, the analyst said he would like to see "more visibility on the outlook of the Pharma business given an upcoming series of patent expirations, including Stelara later this year."
In fact, Divan told investors that his 2025 Pharma sales estimate is below management's expectations.
The analyst also noted that he is below management's expectations for several pipeline assets, which he highlighted as "having $1B or $5B in peak annual sales potential."
* From here: On 2021/11/12, Johnson & Johnson announced its intent to separate its Consumer Health business, creating a new publicly-traded company.
Louise Chen, a bottom 5% analyst from Cantor Fitzgerald reiterates JNJ with a strong buy rating and maintains their JNJ price target from $215.00 to $215.00, on Feb 1, 2023.
Terence Flynn, a top 20% analyst from Morgan Stanley maintains JNJ with a hold rating and raises their JNJ price target from $176.00 to $180.00, on Jan 25, 2023.
Steve Chesney, a top 31% analyst from Atlantic Equities maintains JNJ with a hold rating and raises their JNJ price target from $160.00 to $168.00, on Jan 25, 2023.
David Risinger, a top 9% analyst from SVB Leerink maintains JNJ with a buy rating and lowers their JNJ price target from $194.00 to $186.00, on Jan 20, 2023.
You can dig deeper into what analysts are projecting on the Johnson & Johnson stock forecast page.
Last year, JNJ earnings were $17.94B. In the past 5 year, JNJ's earnings have gone up by 70.07% per year. This was faster than the Drug Manufacturers - General industry average of 25.43%.
Last year, JNJ revenue was $94.94B. In the past five year, JNJ's revenue has increased by 4.43% per year. This was slower than the Drug Manufacturers - General industry average of 8.32%.
Dive into JNJ's earnings and revenue performance here.
In the last year, insiders at JNJ have bought more shares than they have sold.
James D. Swanson, Officer of JNJ, was the latest JNJ insider to sell. They sold $164,094.26 worth of JNJ stock on Mar 6, 2023.
Learn more about who owns JNJ shares here.
Johnson & Johnson pays a dividend of 2.96%, compared to the Drug Manufacturers - General industry's average dividend yield of 3.16%. If you owned $1,000 worth of JNJ stock, you would have been paid $29.61 last year.
Johnson & Johnson dividend payments have consistently grown over the past decade and have remained stable.
Get more info about Johnson & Johnson dividend yield and history here.
One of the reasons eToro is our highest-rated brokerage is because of its social trading community.
Click below to find out what other traders have to say.
You have two main options:
Click the Open Trade button and your broker will place the order.
If you require more help with buying stocks on eToro, watch the helpful video below:
Now that you own some JNJ stock, you'll want to stay up-to-date on your investment.
Create a watchlist to track your JNJ stock.
To summarize, here are the 6 steps for buying Johnson & Johnson stock:
If you require a brokerage, eToro is our favorite option.Get Started with eToro Today
If you would like to monitor your investment in Johnson & Johnson, get started below.
How much does it cost to buy one Johnson & Johnson share?
Is now a good time to buy Johnson & Johnson stock?
What is the best way to buy Johnson & Johnson stock?